Consolidated 2017 revenue: €9.1 million Further growth in sales of LISA TRACKER® kits for routine use: +20% Solid cash position: €5.2 million Croissy-Beaubourg, February 20, 2018, 8:00 CET – Theradiag (ISIN: FR0004197747, ticker: ALTER), a company…
Confirmation of launch of commercial routine use of Renflexis® test Croissy-Beaubourg, January 19, 2018, 8:00 CET – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specialized in in vitro…
LISA TRACKER® monitoring kits have been referenced by MSD France in contracts to supply Remicade® Croissy-Beaubourg, December 21, 2017, 6:00pm CET – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans) a company specialized in…